This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Watson buys Specifar for €400mm to expand into Greece
06 Jun 2011
Strengthening its position in important European countries, Watson Pharmaceuticals Inc. (generics and branded women’s health products) has acquired private generic drug manufacturer Specifar Pharmaceuticals SA for €400mm ($562mm) in cash. Specifar stockholders may also receive up to €40mm in earn-outs related to the first five years of profits for the company’s generic proton pump inhibitor esomeprazole (AstraZeneca’s Nexium), which is awaiting approval and should be launched later this year in key European markets. The earn-outs will be based on sales in major territories in Europe, Asia, Latin America, and Canada.
Payment Includes Cash
Already a Biomedtracker subscriber?You have access to the full deal record through your subscription
Want to become a subscriber?Subscribers get more deal details, updates, deal financials and deal products.Questions?